RU2005114491A - Соединения, составы и способы их использования - Google Patents
Соединения, составы и способы их использования Download PDFInfo
- Publication number
- RU2005114491A RU2005114491A RU2005114491/04A RU2005114491A RU2005114491A RU 2005114491 A RU2005114491 A RU 2005114491A RU 2005114491/04 A RU2005114491/04 A RU 2005114491/04A RU 2005114491 A RU2005114491 A RU 2005114491A RU 2005114491 A RU2005114491 A RU 2005114491A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- alkyl
- phenyl
- hydrogen
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 25
- 238000000034 method Methods 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title 1
- -1 cyano, nitro, methylenedioxy Chemical group 0.000 claims 76
- 229910052739 hydrogen Inorganic materials 0.000 claims 41
- 239000001257 hydrogen Substances 0.000 claims 41
- 125000003107 substituted aryl group Chemical group 0.000 claims 31
- 150000002431 hydrogen Chemical class 0.000 claims 24
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000000547 substituted alkyl group Chemical group 0.000 claims 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 125000003944 tolyl group Chemical group 0.000 claims 14
- 125000004802 cyanophenyl group Chemical group 0.000 claims 11
- 125000004803 chlorobenzyl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000006178 methyl benzyl group Chemical group 0.000 claims 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000002946 cyanobenzyl group Chemical group 0.000 claims 6
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims 6
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004799 bromophenyl group Chemical group 0.000 claims 3
- 125000000068 chlorophenyl group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41788902P | 2002-10-11 | 2002-10-11 | |
| US60/417,889 | 2002-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005114491A true RU2005114491A (ru) | 2006-02-10 |
Family
ID=32094113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005114491/04A RU2005114491A (ru) | 2002-10-11 | 2003-10-02 | Соединения, составы и способы их использования |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7476743B2 (https=) |
| EP (1) | EP1558588A4 (https=) |
| JP (1) | JP2006502219A (https=) |
| KR (1) | KR20050075356A (https=) |
| CN (1) | CN1726198A (https=) |
| AR (1) | AR044193A1 (https=) |
| AU (1) | AU2003282665A1 (https=) |
| BR (1) | BR0315247A (https=) |
| CA (1) | CA2501938A1 (https=) |
| IL (1) | IL167936A0 (https=) |
| IS (1) | IS7798A (https=) |
| MX (1) | MXPA05003830A (https=) |
| NO (1) | NO20052267L (https=) |
| NZ (1) | NZ539643A (https=) |
| PL (1) | PL375889A1 (https=) |
| RU (1) | RU2005114491A (https=) |
| TW (1) | TW200418818A (https=) |
| WO (1) | WO2004032840A2 (https=) |
| ZA (1) | ZA200503733B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2522450C2 (ru) * | 2008-08-07 | 2014-07-10 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд. | Соединения, оказывающие возбуждающее действие на рецептор активатора пролиферации пероксисом подтипа б, способ получения и применение указанных соединений |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101170925B1 (ko) * | 2004-06-18 | 2012-08-07 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물 |
| CN101027309B (zh) | 2004-08-18 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途 |
| DE102006023337A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | Triazolderivate II |
| JP5343363B2 (ja) * | 2008-01-31 | 2013-11-13 | アイシン精機株式会社 | シートクッション調整装置 |
| JP2013523867A (ja) | 2010-04-15 | 2013-06-17 | ノバルティス アーゲー | Ｋｓｐ阻害剤としてのトリアゾール化合物 |
| WO2012095691A1 (en) * | 2011-01-15 | 2012-07-19 | Jubilant Life Sciences Ltd. | An improved process for producing aminopyridines |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| AU2013363398B2 (en) | 2012-12-20 | 2017-06-01 | Tempest Therapeutics, Inc. | Triazolone compounds and uses thereof |
| US9776976B2 (en) | 2013-09-06 | 2017-10-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| RU2751512C2 (ru) | 2015-06-22 | 2021-07-14 | Байер Фарма Акциенгезельшафт | Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы |
| TW201722958A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產（第二）有限公司 | 化學化合物 |
| JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ） |
| US20250215039A1 (en) * | 2022-03-30 | 2025-07-03 | Primefour Therapeutics, Inc. | Nucleosides for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE793532A (fr) * | 1971-12-29 | 1973-06-29 | Upjohn Co | Nouvelles 1,2,4-triazol-3-ones et leur preparation |
| US3748339A (en) * | 1972-05-05 | 1973-07-24 | Upjohn Co | 2-(3-(1-(dimethylamino)alkyl)-1,5-dihydro-5-oxo - 1 - substituted-4h-1,2,4-triazol-4-yl)benzophenone and process |
| IT1068010B (it) * | 1976-11-17 | 1985-03-21 | Montedison Spa | Nuovi esteri fosforici derivati dall' 1-2-4 triazolo ad azione insetticida,nematocida e acaricida e loro preparazione |
| NL7712430A (nl) * | 1976-11-17 | 1978-05-19 | Montedison Spa | Nieuwe fosforzuuresters, afgeleid van 1.2.4- -triazool, met een insecticide, nematocide en acaricide werking en werkwijze ter bereiding daarvan. |
| US4487773A (en) * | 1981-03-16 | 1984-12-11 | Mead Johnson & Company | 1,2,4-Triazol-3-one antidepressants |
| US5250558A (en) * | 1992-01-28 | 1993-10-05 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis |
| GB9211193D0 (en) * | 1992-05-27 | 1992-07-08 | Merck Sharp & Dohme | Therapeutic agents |
| IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
| AU722883B2 (en) * | 1995-10-18 | 2000-08-10 | Merck & Co., Inc. | Cyclopentyl tachykinin receptor antagonists |
| JP2002234874A (ja) * | 2000-09-26 | 2002-08-23 | Tanabe Seiyaku Co Ltd | ５−フェニルベンジルアミン誘導体、その製法及びその合成中間体 |
| WO2002034699A2 (en) * | 2000-10-26 | 2002-05-02 | Merck & Co., Inc. | Mammalian metabolites of a tachykinin receptor antagonist |
| MXPA04012642A (es) * | 2002-06-14 | 2005-03-23 | Merck & Co Inc | Inhibidores de la cinesina mitotica. |
-
2003
- 2003-10-02 PL PL03375889A patent/PL375889A1/xx unknown
- 2003-10-02 MX MXPA05003830A patent/MXPA05003830A/es unknown
- 2003-10-02 KR KR1020057006260A patent/KR20050075356A/ko not_active Withdrawn
- 2003-10-02 RU RU2005114491/04A patent/RU2005114491A/ru not_active Application Discontinuation
- 2003-10-02 CN CNA200380105737XA patent/CN1726198A/zh active Pending
- 2003-10-02 US US10/529,634 patent/US7476743B2/en not_active Expired - Fee Related
- 2003-10-02 EP EP03774548A patent/EP1558588A4/en not_active Withdrawn
- 2003-10-02 WO PCT/US2003/031413 patent/WO2004032840A2/en not_active Ceased
- 2003-10-02 BR BR0315247-2A patent/BR0315247A/pt not_active IP Right Cessation
- 2003-10-02 CA CA002501938A patent/CA2501938A1/en not_active Abandoned
- 2003-10-02 JP JP2004543136A patent/JP2006502219A/ja active Pending
- 2003-10-02 NZ NZ539643A patent/NZ539643A/en unknown
- 2003-10-02 AU AU2003282665A patent/AU2003282665A1/en not_active Abandoned
- 2003-10-09 AR ARP030103684A patent/AR044193A1/es unknown
- 2003-10-09 TW TW092128029A patent/TW200418818A/zh unknown
-
2005
- 2005-04-10 IL IL167936A patent/IL167936A0/en unknown
- 2005-04-11 IS IS7798A patent/IS7798A/is unknown
- 2005-05-10 NO NO20052267A patent/NO20052267L/no not_active Application Discontinuation
- 2005-05-10 ZA ZA200503733A patent/ZA200503733B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2522450C2 (ru) * | 2008-08-07 | 2014-07-10 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд. | Соединения, оказывающие возбуждающее действие на рецептор активатора пролиферации пероксисом подтипа б, способ получения и применение указанных соединений |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05003830A (es) | 2005-06-23 |
| PL375889A1 (en) | 2005-12-12 |
| NO20052267L (no) | 2005-05-31 |
| AR044193A1 (es) | 2005-09-07 |
| AU2003282665A1 (en) | 2004-05-04 |
| EP1558588A4 (en) | 2006-11-02 |
| EP1558588A2 (en) | 2005-08-03 |
| TW200418818A (en) | 2004-10-01 |
| CN1726198A (zh) | 2006-01-25 |
| ZA200503733B (en) | 2006-02-22 |
| NZ539643A (en) | 2006-11-30 |
| US20060189671A1 (en) | 2006-08-24 |
| IL167936A0 (en) | 2009-02-11 |
| CA2501938A1 (en) | 2004-04-22 |
| WO2004032840A2 (en) | 2004-04-22 |
| US7476743B2 (en) | 2009-01-13 |
| BR0315247A (pt) | 2005-08-30 |
| JP2006502219A (ja) | 2006-01-19 |
| WO2004032840A3 (en) | 2004-10-14 |
| IS7798A (is) | 2005-04-11 |
| KR20050075356A (ko) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005114491A (ru) | Соединения, составы и способы их использования | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
| RU2004133325A (ru) | Соединения, композиции на их основе и способы их использования | |
| BG106095A (bg) | Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици | |
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| JP2005536475A5 (https=) | ||
| JP2006502219A5 (https=) | ||
| DK1682178T3 (da) | Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet | |
| ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
| EP2037925B1 (en) | Combinations comprising 5ht6 modulators and cholinesterase inhibitors | |
| TW200621249A (en) | Substituted amide beta secretase inhibitors | |
| DE60003837D1 (de) | Tetrapeptid, das die funktionelle aktivität von neuronen stimuliert, dieses enthaltendes pharmakologisches mittel und seine verwendung | |
| CO5160329A1 (es) | Metodo para proveer absorcion incrementada de una amina far- maceuticamente aceptable en la sangre de un humano y composi cion que comprende una amina farmaceuticamente un farmaco antiinflamatorio no esteroidal | |
| SE9900961D0 (sv) | Novel compounds | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
| SE0301701D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| JP2005533119A5 (https=) | ||
| EA200601249A1 (ru) | Пиперазины, пригодные для лечения боли | |
| AU2012213036A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| EA200401303A1 (ru) | Лекарственные средства, содержащие стероиды и новое антихолинергическое средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080117 |